GS010

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Optic, Atrophy, Hereditary, Leber

Conditions

Optic, Atrophy, Hereditary, Leber

Trial Timeline

Jan 1, 2016 → Dec 1, 2018

NCT ID

NCT02652780

About GS010

GS010 is a phase 3 stage product being developed by GenSight Biologics for Optic, Atrophy, Hereditary, Leber. The current trial status is completed. This product is registered under clinical trial identifier NCT02652780. Target conditions include Optic, Atrophy, Hereditary, Leber.

What happened to similar drugs?

4 of 13 similar drugs in Optic, Atrophy, Hereditary, Leber were approved

Approved (4) Terminated (4) Active (7)

✅Satralizumab 120 mgChugai PharmaceuticalApproved

🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3

🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3

🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3

🔄SatralizumabRochePhase 3

✅InebilizumabAmgenApproved

❌Zyvox - linezolid + Matched controlPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02652767	Phase 3	Completed	Feb 23, 2016	Jul 4, 2019	Optic, Atrophy, Hereditary, Leber
NCT02652780	Phase 3	Completed	Jan 1, 2016	Dec 1, 2018	Optic, Atrophy, Hereditary, Leber

Competing Products

20 competing products in Optic, Atrophy, Hereditary, Leber

See all competitors

Product	Company	Stage	Hype Score
Satralizumab 120 mg	Chugai Pharmaceutical	Approved	35
Satralizumab + Placebo + Baseline Treatment	Chugai Pharmaceutical	Phase 3	40
Satralizumab + Placebo	Chugai Pharmaceutical	Phase 3	40
PDE5 Inhibitors	Eli Lilly	Pre-clinical	26
Atacicept + Placebo matched to atacicept	Merck	Phase 2	27
Fingolimod 0.5mg/daily + Placebo	Novartis	Phase 2	27
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids	Roche	Phase 3	40
Satralizumab	Roche	Phase 3	47
UPLIZNA	Amgen	Pre-clinical	33
Inebilizumab	Amgen	Phase 2	42
Inebilizumab	Amgen	Approved	47
Zyvox - linezolid + Matched control	Pfizer	Phase 3	32
Dexmedetomidine HCL Injection + Placebo	Pfizer	Phase 3	40
No intervention	Pfizer	Pre-clinical	26
Efgartigimod Alfa + Placebo	Argenx	Phase 2	39
Diagnostic procedures	Bayer	Approved	32
Placebo + BIIB033 100mg/Kg	Biogen	Phase 2	32
BIIB033 (anti-LINGO-1 mAb) + Placebo	Biogen	Phase 2	32
intravenous methylprednisolone	Brain Biotech	Pre-clinical	23
OCS-05 +SoC (corticosteroid) IV administration	Oculis Holding AG	Phase 2	29